David Benton, MD
Hematology & Oncology · Topsham, MENPI 1336346501
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,128 of the $3,304 with a category attached, or 64.4%. Reflexion Medical, Inc. accounts for 69.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $2,423 and has fallen 90.0% since, to $243 in 2025.
Across 43 payments — averaging $76.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reflexion Medical, Inc.$2K
- AbbVie$211
- Boston Scientific$152
- Pharmacyclics LLC, An Abbvie Company$129
- Johnson & Johnson$88
- Pfizer$71
- plus $349 from 14 others
Across 5 payments — averaging $5345.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$27K
What the payments were for
- Travel & lodging$2,12864%
- Food & beverage$1,04332%
- Education$1334%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reflexion Medical, Inc. | 4 | $2,303 |
| AbbVie(2 entities) | 8 | $211 |
| Boston Scientific | 3 | $152 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $129 |
| Johnson & Johnson(2 entities) | 3 | $88 |
| Pfizer | 4 | $71 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Genentech USA, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Novartis | 1 | $28 |
| Dermira, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Smith+Nephew | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,304 in reported general payments places this provider in the 70th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 94 | $1,602,010 |
| ErleadaApalutamide | 103 | $1,509,488 |
| NubeqaDarolutamide | 88 | $1,186,515 |
| PomalystPomalidomide | 40 | $828,167 |
| ImbruvicaIbrutinib | 42 | $818,522 |
| Abiraterone Acetate | 283 | $713,297 |
| JakafiRuxolitinib Phosphate | 49 | $674,312 |
| VenclextaVenetoclax | 37 | $669,899 |
| BesremiRopeginterferon Alfa-2b-Njft | 31 | $531,341 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 49 | $467,286 |
| BrukinsaZanubrutinib | 31 | $456,837 |
| TagrissoOsimertinib Mesylate | 23 | $364,471 |
| IbrancePalbociclib | 20 | $298,122 |
| MekinistTrametinib Dimethyl Sulfoxide | 24 | $290,866 |
| BosulifBosutinib | 14 | $256,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $15 | $1,602,01094 claims |
| Johnson & JohnsonErleada, Xarelto | $88 | $1,566,275157 claims |
| AbbVieVenclexta, Lupron Depot | $211 | $878,96379 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $35 | $828,16740 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $129 | $818,52242 claims |
| NovartisMekinist, Tasigna, Tafinlar | $28 | $781,30158 claims |
| PfizerIbrance, Bosulif, Eliquis | $71 | $632,083138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Topsham
- Brian HaneyTopsham$12K
- Julia MoukharskayaTopsham$595
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Helen RyanKennebunk$83K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
- Tracey WeisbergWestbrook$31K
- Daniel RauschWestbrook$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.